Why Professional Traders Are Buying Biotechnology Shares in Market Decline

Biotech valuations have compressed to multi-decade lows despite 56% sector outperformance, creating selective buying opportunities for professional traders.

Biotech valuations have compressed to multi-decade lows despite 56% sector outperformance, creating selective buying opportunities for professional traders.

GRNJ's actively managed small- and mid-cap fund is beating major passive indices in 2026 despite higher fees, driven by AI infrastructure exposure and strategic sector positioning.

The Bank of Korea's first hike since 2023 took direct aim at leveraged Samsung and SK Hynix ETFs — and the KOSPI fell 6.48% in one day.

Scandic Hotels' Q2 2026 results show a 59% EBITDA decline amid corporate travel weakness, though management projects margin recovery to 13%+ in H2.

Robinhood prediction markets for July 14 morning are actively pricing Ethereum's expected range, with CoinCodex and Changelly offering competing forecasts.

SK Hynix's US listing trades at a 36% premium to Seoul, reflecting AI chip shortage and manufacturing strategy.

When uric acid crystallizes in your joints, it sparks a severe inflammatory reaction—and understanding MSU crystals is key to preventing gout.

AbbVie's $10.9 billion Apogee acquisition expands immunology assets but creates near-term dividend uncertainty during integration.
SK Hynix's Nasdaq debut and Micron's sold-out HBM capacity set up a choice between proven dominance and supply-driven upside.

Samsung's profit explosion from AI demand sparked a surprising investor exodus from technology stocks into overlooked financial and communications sectors.